Phalguni Deswal
LightNews LightNews
phalguniddw.bsky.social
Phalguni Deswal
@phalguniddw.bsky.social
18 followers 11 following 180 posts
Editor - Drug and Device World
Posts Replies Media Videos
phalguniddw.bsky.social
New data from Nektar Therapeutics shows REZPEG, an investigational eczema treatment, also improved asthma symptoms in patients with both conditions. A potential dual-benefit therapy.

#News #dermatitis #asthma #clinicaltrial #biologic #Treg #AtopicDermatitis
Nektar’s Treg therapy shows promise in dermatitis and asthma
Treg-targeting biologic, rezpegaldesleukin (Rezpeg), demonstrates significant improvement in asthma control for patients with atopic dermatitis.
druganddeviceworld.com
November 13, 2025 at 4:33 PM
phalguniddw.bsky.social
New data by Teva Pharmaceuticals show Austedo & Austedo XR reduce involuntary movements and improve quality of life for people with tardive dyskinesia.
#News #TardiveDyskinesia #AUSTEDO #Teva #Neurology #MentalHealth
Teva unveils real-world findings for tardive dyskinesia treatment
Teva’s latest study finds Austedo and Austedo XR reduce involuntary movements and improve quality of life in tardive dyskinesia patients.
druganddeviceworld.com
November 13, 2025 at 4:06 PM
phalguniddw.bsky.social
Amgen's Repatha cuts risk of first major heart attack or stroke by 25% in high-risk patients. New data at AHA

#News #AHA25 #HeartHealth #CardiovascularRisk #Prevention #Repatha #HeartAttack
AHA 2025: Amgen’s Repatha cuts first heart event risk by 25% 
Landmark trial shows Repatha significantly reduces major cardiovascular events in high-risk patients without prior heart attack or stroke.
druganddeviceworld.com
November 13, 2025 at 2:35 PM
phalguniddw.bsky.social
New human data for cancer therapy Molecular Partners' MP0712 shows precise tumor targeting & limited healthy organ exposure. Phase 1 trial expected by end of 2025.

#News #CancerResearch #Radiopharmaceuticals #SCLC #Oncology
Molecular unveils first human data for cancer radiotherapy
The company reveals first human data for its DLL3-targeting radiopharmaceutical MP0712, showing precise tumor targeting and limited healthy organ exposure.
druganddeviceworld.com
November 13, 2025 at 2:07 PM
phalguniddw.bsky.social
Chiesi Group licenses AbbVie's Aliada Therapeutics blood-brain barrier tech to develop new therapies for rare neurological disorders.
#News #RareDisease #Biotech #Neurology #Innovation #Partnership
Chiesi licenses AbbVie unit’s brain-targeting tech for rare diseases
The partnership with Aliada Therapeutics centers on a platform technology designed to ferry large-molecule therapies across the protective blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).
druganddeviceworld.com
November 13, 2025 at 1:38 PM
phalguniddw.bsky.social
Modulight Biotherapeutics secures $12.2M seed funding to advance its precise optogenetic therapy for neurological disorders like chronic pain and epilepsy.

#News #Optogenetics #Biotech #Neurology #Funding #Neurotech #MedTech #Innovation
Modulight secures $12 million for neurological disorders treatment
The company closed a seed funding round to advance its novel optogenetic platform for treating neurological disorders like chronic pain and epilepsy.
druganddeviceworld.com
November 13, 2025 at 10:07 AM
phalguniddw.bsky.social
FDA clears Stereotaxis' next-gen GenesisX surgical robot. Compact design breaks down adoption barriers, expanding access to life-saving cardiac care.

#News #robotics #healthtech #FDAapproval #medtech #surgicalrobot
Stereotaxis gains FDA nod for next-gen surgical robot
New GenesisX system eliminates key infrastructure barriers, broadening access to robotic electrophysiology procedures.
druganddeviceworld.com
November 13, 2025 at 9:43 AM
phalguniddw.bsky.social
MMI earns IDE approval from the US FDA for a groundbreaking robotic microsurgery trial targeting Alzheimer’s disease.

#News #Alzheimers #Surgery #Neurosurgery #Neurology #ClinicalTrial #FDAapproval #medicaldevice
FDA approves first robotic microsurgical study in Alzheimer’s
MMI earns FDA IDE approval for a groundbreaking robotic microsurgery trial targeting Alzheimer’s disease.
druganddeviceworld.com
November 7, 2025 at 10:55 AM
phalguniddw.bsky.social
Phenomix Sciences unveils new data at #Obesity"/hashtag/ObesityWeek2025" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ObesityWeek2025 showing its #MyPhenome test accurately predicts #GLP1 therapy response and obesity risk across diverse populations.

#News #PrecisionMedicine #ObesityResearch #HealthcareInnovation #Genomics #WeightLoss #Obesity
Phenomix expands evidence for GLP-1 response predicting MyPhenome test
New data show the MyPhenome test accurately predicts GLP-1 response and obesity risk across diverse populations.
druganddeviceworld.com
November 4, 2025 at 7:01 PM
phalguniddw.bsky.social
AAVantgarde Bio has raised $141M in Series B funding to advance gene therapies for Stargardt disease and Usher 1B syndrome — two inherited retinal diseases.

#News #Biotech #GeneTherapy #Ophthalmology #RareDiseases #LifeSciences #Stargardt #UsherSyndrome #HealthInnovation
AAVantgarde closes $141 million Series B for genetic disease therapies
The company plans to use the Series B funding to progress clinical trials for two genetic eye disorders, Stargardt disease and Usher 1B syndrome.
druganddeviceworld.com
November 4, 2025 at 6:16 PM
phalguniddw.bsky.social
Intensity Therapeutics's INT230-6, a tumor-injectable therapy, improved survival and showed abscopal effects in patients with advanced, refractory cancers.

#News #Cancer #Oncology #CancerResearch #IJTHS #CancerSurvival #ClinicalTrial
Intensity bolsters survival data for its intratumoral cancer therapy
The company’s stock shot up by approximately 394%, driven by the cancer therapy's strong overall survival and disease control results.
druganddeviceworld.com
November 4, 2025 at 5:32 PM
phalguniddw.bsky.social
🚀 CustoMED raises $6M to advance orthopedic surgery with AI-powered, 3D printed, patient-specific implants and tools. 🌍💡

#News #MedTech #AIinHealthcare #3DPrinting #OrthopedicSurgery #Innovation #HealthTech #StartupNews
CustoMED raises $6 million to expand AI-driven 3D printing for orthopedic surgery
Israeli medtech startup plans to use the funding to expand orthopedic applications, pursue global approvals, and scale manufacturing.
druganddeviceworld.com
October 29, 2025 at 5:15 PM
phalguniddw.bsky.social
Kymera Therapeutics has presented new preclinical data for its investigational drug, KT-579, an oral treatment designed to target a key driver of autoimmune diseases at ACT 2025 in Chicago.

#News #ClinicalResearch #autoimmune #lupus #SLE #arthritis #Sjögren's #ACR25
Kymera unveils preclinical data for oral autoimmune therapy
The Massachusetts-based company’s oral therapy KT-579 shows promise in preclinical models for lupus, rheumatoid arthritis, and Sjögren's syndrome.
druganddeviceworld.com
October 29, 2025 at 4:39 PM
phalguniddw.bsky.social
ten23 health and Neumirna Therapeutics have joined forces to advance NMT.001, an RNA-based therapy aimed at treating drug-resistant epilepsy.

#News #RNAtherapy #EpilepsyResearch #BiotechInnovation #ten23health #NeumirnaTherapeutics #Neurology #OligonucleotideTherapy #LifeSciences
ten23 health and Neumirna partner to advance RNA therapy for epilepsy
The collaboration seeks to advance NMT.001, an RNA-based therapy targeting microRNAs involved in drug-resistant epilepsy.
druganddeviceworld.com
October 28, 2025 at 4:24 PM
phalguniddw.bsky.social
Affibody's izokibep shows strong long-term results in psoriatic arthritis. New 52-week data from a Phase IIb/III trial presented at the ACR conference in Chicago

#News #PsoriaticArthritis #Rheumatology #ClinicalTrials #IL17 #Izokibep #ACR2025 #MedicalResearch
Affibody’s psoriatic arthritis therapy shows long-term promise
New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.
druganddeviceworld.com
October 27, 2025 at 5:16 PM
phalguniddw.bsky.social
News for prostate cancer patients in England and Wales — NICE has recommended Bayer’s Nubeqa plus ADT as a new NHS treatment option for men with hormone-sensitive metastatic prostate cancer.

#News #ProstateCancer #NICE #Bayer #Nubeqa #Darolutamide #CancerResearch #MensHealth #Oncology #NHS
Bayer scores UK NICE nod for Nubeqa in prostate cancer
NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.
druganddeviceworld.com
October 27, 2025 at 4:49 PM
phalguniddw.bsky.social
A new Danish study shows cryoablation is just as effective as robotic surgery for kidney cancer — but 32% cheaper and with shorter hospital stays. 🌍💙❄️

#News #KidneyCancer #Cryoablation #HealthcareInnovation #MedicalResearch #CancerTreatment #BostonScientific
Boston Scientific study finds cryoablation more cost-effective than surgery
A Danish study finds cryoablation equally effective as robotic surgery for kidney cancer, but at 32% lower cost in patients with kidney cancer.
druganddeviceworld.com
October 27, 2025 at 9:58 AM
phalguniddw.bsky.social
Hyfe’s AI-powered Behavioral Cough Suppression Therapy reduced chronic cough frequency by over 40% and improved quality of life for 80% of participants.

#News #DigitalHealth #ClinicalResearch #AIHealthcare #ChronicCough #DigitalTherapeutics #HealthInnovation
Hyfe bolsters clinical data for chronic cough digital therapeutic
Hyfe’s AI-driven digital cough therapy reduced cough frequency by more than 40% in patients suffering from refractory and unexplained chronic cough.
druganddeviceworld.com
October 23, 2025 at 7:17 PM
phalguniddw.bsky.social
Telix Pharmaceuticals doses first patient in its SOLACE trial, testing a non-opioid radiopharmaceutical for advanced cancer pain.

#News #Oncoloy #ClinicalTrial #PainRelief #Research
Telix starts clinical trial for pain therapy for metastatic bone cancer
Telix Pharmaceuticals doses first patient in its SOLACE trial, testing a non-opioid radiopharmaceutical for advanced cancer pain.
druganddeviceworld.com
October 23, 2025 at 7:01 PM
phalguniddw.bsky.social
The FDA has approved a new use for Novo Nordisk's oral semaglutide, Rybelsus, expanding its label to reduce cardiovascular risk in high-risk adults with type 2 diabetes.

#News #diabetes #type2diabetes #Obesity #FDAapproval
FDA expands Novo Nordisk’s Rybelsus label to include cardiovascular risk reduction
The FDA has approved a new use for Novo Nordisk's oral semaglutide, expanding its label to reduce cardiovascular risk in high-risk adults with type 2 diabetes.
druganddeviceworld.com
October 22, 2025 at 5:11 PM
phalguniddw.bsky.social
Sanofi presents data from a Phase II clinical trial for an investigational targeted alpha therapy, AlphaMedix , as a treatment approach for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at #ESMOef="/hashtag/ESMO25" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ESMO25.

#News #ESMO #CancerResearch #ClinicalTrial #cancer #oncology
ESMO 2025: Promising Phase II data for Sanofi’s alpha therapy
Investigational targeted alpha therapy AlphaMedix shows clinical activity in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
druganddeviceworld.com
October 21, 2025 at 4:33 PM
phalguniddw.bsky.social
Biotech firm I-Mab unveils global transformation, dual listing plan (US NASDAQ and Hong Kong Stock Exchange), and new focus under the NovaBridge Biosciences name.

#News #Rebrand #IPO #AMD #DME #CancerResearch
I-Mab to rebrand as NovaBridge Biosciences, pursue Hong Kong IPO
Biotech firm I-Mab unveils global transformation, dual listing plan, and new focus under the NovaBridge Biosciences name.
druganddeviceworld.com
October 21, 2025 at 1:54 PM
phalguniddw.bsky.social
Grifols plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

#News #USAref="/hashtag/USAmanufacturing" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#USAmanufacturing #manufacturing #onshoring #USA #Grifols #BloodTransusion
Grifols expands US diagnostic manufacturing with new San Diego facility
The company plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.
druganddeviceworld.com
October 21, 2025 at 1:37 PM
phalguniddw.bsky.social
Enterome’s OncoMimics immunotherapy EO2463 gains FDA Fast Track for follicular lymphoma, paving the way for Phase III trials in in the low-tumor-burden “watch-and-wait” setting.

#News #Lymphoma #FDAfasttrack #CancerResearch #Enterome #Oncology
Enterome’s lymphoma drug wins FDA fast track designation
The company is exploring EO2463’s efficacy in relapsed or refractory settings in a Phase I/II trial, with plans to start Phase III registrational trial in a “watch-and-wait” iNHL patient population
druganddeviceworld.com
October 21, 2025 at 1:16 PM
phalguniddw.bsky.social
AbbVie's New IBD data shows endoscopic healing in Crohn's predicts long-term success. Real-world evidence for UC treatment confirms rapid symptom relief. #News #CrohnsDisease #UlcerativeColitis #IBD #EndoscopicHealing
UEGW 2025: AbbVie bolsters IBD data for Rinvoq and Skyrizi
New data and lead investigators also reinforce the importance of treating beyond symptoms in Crohn's disease and ulcerative colitis.
druganddeviceworld.com
October 16, 2025 at 5:04 PM